DRAPER, Utah, March 18, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (Nasdaq: HQY) ("HealthEquity") HealthEquity, the nation’s largest Health Savings Account (HSA) administrator, today announced the launch of HealthEquity Assist™, a suite of tools that help members save, spend, and invest for healthcare. By using HealthEquity Assist, employers are enabled with greater visibility into their benefits program performance and can drive positive financial and health actions to support their workforce.
The smart technology offering was developed to alleviate common employee pain points with their benefits — including rising healthcare costs, which are expected to increase by 9% in 20251, a complex and fragmented benefits landscape that is difficult to navigate, and limited resources available to support benefit education and personalized insights.
“Cost and complexity are extremely challenging aspects of the benefits industry, for employers and employees,” HealthEquity SVP Client and Partner Services, Melissa Phillips said. “In collaboration with our clients, we’ve come to believe that for benefits to be truly self-directed, benefits leaders and team members need to have access to a deeper level of data, insights, and understanding.”
The three initial HealthEquity Assist offerings integrate quickly into existing company platforms, processes, and workflows. The offerings include:
“In the past, I have struggled with fitting everything together and being able to dig deeper to identify trends and view metrics on our employees' patterns. HealthEquity Analyzer has helped us paint a picture of how our employees utilize the Health Savings Account,” said Nick Hawes, benefits coordinator at town of Shrewsbury, Massachusetts. “It allows us to get an idea of spending versus savings habits and what's really happening behind the contributions that we put in the accounts.”
Employers can incorporate the tools into their current benefits ecosystem with support from HealthEquity experts and learn more about HealthEquity Assist by visiting https://www.healthequity.com/assist-portfolio.
"At HealthEquity, we believe all members deserve a benefits experience that’s seamless and intuitive—one that empowers them to make better decisions for their health and financial wellbeing,” said HealthEquity CEO Scott Cutler. “The HealthEquity Assist portfolio is another example of how we support our members, clients, and partners at every stage of their benefits journey. We’re not simply responding to change—we’re actively shaping the future of benefits technology, creating a more impactful experience for everyone.”
Resources:
1 Click Here.
About HealthEquity
HealthEquity and its subsidiaries administer HSAs and various other consumer-directed benefits for over 17 million accounts, working in close partnership with employers, benefits advisors, and health and retirement plan providers who share our unwavering commitment to our mission of saving and improving lives by empowering healthcare consumers. Through cutting-edge solutions, innovation, and a relentless focus on improving health outcomes, we empower individuals to take control of their healthcare journey while ultimately enhancing their overall well-being. Learn more about our “Purple service” and approach at www.healthequity.com.
Media Contact
Amy Cerny
This email address is being protected from spambots. You need JavaScript enabled to view it.
For the latest HealthEquity news, research and more visit our newsroom at https://www.healthequity.com/newsroom
© 2025 HealthEquity, Inc. All rights reserved.
HealthEquity, HealthEquity Assist, HealthEquity Analyzer, HealthEquity Navigator and HealthEquity Momentum are trademarks of HealthEquity, Inc.
Last Trade: | US$84.52 |
Daily Change: | 2.03 2.46 |
Daily Volume: | 934,108 |
Market Cap: | US$7.320B |
March 18, 2025 February 18, 2025 January 13, 2025 November 12, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load